Qulipta is an oral atogepant medicine for preventing migraine in adults. Episodic and chronic migraine have different prescribing qualifications, especially when kidney function or interacting medicines affect treatment.
The approved uses and formulations described here follow US prescribing information. They may differ in other countries.
| Medicine detail | Details |
|---|---|
| Active ingredient(s) | atogepant |
| Medicine class | Calcitonin gene-related peptide (CGRP) receptor antagonist |
| Forms and strengths | Oral tablets: 10, 30 and 60 mg |
Prevention is the intended role
Qulipta is US-labeled for preventive treatment of migraine in adults. It is used on a scheduled plan rather than as a substitute for an acute rescue prescription. The clinician should explain which medicine addresses an attack and which addresses prevention, including how treatment response will be reviewed.
Source: [1]
Tablet strengths and migraine type
The tablets contain 10, 30 or 60 mg of atogepant and may be taken with or without food. The label distinguishes episodic from chronic migraine in its dosing recommendations. Those distinctions should remain on the prescribing plan instead of being inferred from an online tablet list.
Source: [1]
Kidney, liver and interaction qualifications
Severe kidney impairment and end-stage renal disease have different recommendations for episodic and chronic migraine; use for chronic migraine is not recommended in those settings. Severe liver impairment is another reason to avoid treatment. CYP3A4 and OATP interactions can also change the prescribed approach and need a pharmacist's check.
Source: [1]
Safety issues during continued treatment
The label warns about serious hypersensitivity, new or worsening hypertension and Raynaud's phenomenon. Some allergic reactions are delayed. Nausea, constipation and fatigue or sleepiness are common reported reactions. Severe reactions require prompt assessment; report blood-pressure changes or new circulation symptoms to the prescribing team.
Source: [1]
Review benefit without self-adjustment
An ongoing prevention plan should include a way to review migraine frequency, tolerability and the need for acute medicines. Do not increase the tablet strength or combine preventive CGRP products independently. A different tablet acting on a similar pathway may have different approved uses and repeat-dose restrictions.
For related product context, see the Qulipta and NURTEC ODT comparison; treatment changes still require a prescribing review.
Source: [1]
Questions and answers
Can Qulipta be used only when an attack begins?
Its labeled role is scheduled migraine prevention. Acute treatment should follow the separate plan provided by the clinician.
Do kidney restrictions differ by migraine type?
Yes. The label distinguishes episodic and chronic migraine when severe renal impairment or end-stage renal disease is present.
Does Qulipta have to be taken with a meal?
The cited label permits administration with or without food. Follow the prescribed schedule and interaction instructions.
Related reading
Sources
Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026